In 2023, international pharmaceutical firms supplied clinical trial medications to local patients valued at approximately 320.8 billion. The overall quantity of clinical trials carried out that year was 1,723, reflecting a 7.7 percent rise...
SystImmune, Inc (SystImmune), a biotechnology company in the clinical stage, declared that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC)...
CytoDyn Inc., a biotech firm working on leronlimab, a CCR5 inhibitor with possible therapeutic uses, revealed that it has obtained approval from the US FDA to begin its phase II cancer trial. The research will assess how effective leronlimab is...
.JPG)
HuidaGene Therapeutics (HuidaGene), a worldwide biotech company focused on genome medicines in clinical trials, revealed that the US FDA has approved its HG202 investigational new drug (IND) application for neovascular age-related macular...
A graphene-based brain chip is entering its first clinical trial at Salford Royal Hospital, aiming to revolutionize brain tumor surgeries, according to The Guardian. The device, roughly postage-stamp sized, works by detecting cancer cells through ...
Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for a long-acting injectable (LAI) preventive compound for malaria. The trial, conducted in healthy volunteers in Nottingham, UK, marks a significant...
Tyra Biosciences, Inc., a biotechnology company in the clinical development stage, revealed that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for TYRA-300, enabling the company to move...
Lyell Immunopharma, Inc, located in South San Francisco, revealed that it has finalized a deal to purchase ImmPACT Bio USA Inc, a clinical-stage biotech company, as part of its efforts to develop advanced CAR T-cell therapies for cancer...
Abbott introduced a unique clinical trial aimed at enhancing results in patients with worsening heart failure who may benefit from advanced treatment choices. The TEAM-HF study aims to include a maximum of 850 participants from 75 locations...
Dr. Poovamma CU - Senior Consultant & Director - Breast Oncology, Cytecare Hospitals in a recent interaction with India Pharma Outlook shares her views on how innovations such as AI-driven imaging
, CDSCO.jpg)
